Kutteh 1996a.

Methods	Single centre, quasi‐randomised (alternatively assigned to treatment) non‐blinded, non‐placebo controlled.
Participants	Inclusion criteria: 1) Desire to become pregnant. 2) Agreement to be completely evaluated. 3) >/= 3 consecutive pregnancy losses. 4) Consent to alternative treatment assignment. 5) +ve APL antibody on at least 2 occasions determined by IgG ACL or antiphosphotidylserine > 27 GPL units or IgM ACL or antiphosphotidylserine > 23 MPL units. Exclusion criteria: 1) SLE. 2) Positive LA. 3) Presence of another abnormal test result. 4) Aspirin allergy. 5) Other reason for anticoagulation. 6) Refused treatment or allocation.
Interventions	Heparin 5000 units twice daily sc plus aspirin 81 mg/day versus aspirin 81 mg/day. Heparin dose increased by 1000 units/dose weekly until PTT 1.2 ‐ 1.5 times baseline.
Outcomes	Multiple obstetric and neonatal outcomes.
Notes	Aspirin commenced before conception. Heparin commenced at the first confirmed pregnancy test (5.3 weeks postgestation).
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	High risk	C ‐ Inadequate